<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer Treatment Accessibility &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cancer-treatment-accessibility/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 13:38:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Cancer Treatment Accessibility &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Breakthrough AI Tool Leverages Routine Blood Tests to Forecast Immunotherapy Outcomes Across Diverse Cancers</title>
		<link>https://bioengineer.org/breakthrough-ai-tool-leverages-routine-blood-tests-to-forecast-immunotherapy-outcomes-across-diverse-cancers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 06 Jan 2025 20:29:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Artificial intelligence in oncology]]></category>
		<category><![CDATA[Blood Test Biomarkers]]></category>
		<category><![CDATA[Cancer Treatment Accessibility]]></category>
		<category><![CDATA[Immunotherapy Response Prediction]]></category>
		<category><![CDATA[Machine Learning in Healthcare]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-ai-tool-leverages-routine-blood-tests-to-forecast-immunotherapy-outcomes-across-diverse-cancers/</guid>

					<description><![CDATA[In a significant advancement for cancer treatment, researchers have unveiled a groundbreaking model designed to enhance the prediction of patient responses to immune checkpoint inhibitors. These inhibitors represent a class of drugs within immunotherapy that have demonstrated remarkable potential in cancer management. However, they are not effective for everyone, which has prompted a global need [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233161</post-id>	</item>
	</channel>
</rss>
